The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Preexposure Prophylaxis for HIV Prevention: Where Have We Been and Where Are We Going?
Open accessAbstract
Preexposure prophylaxis (PrEP), in which HIV-uninfected persons with ongoing HIV risk use antiretroviral medications to reduce their risk of acquiring HIV infection, is an efficacious and promising new HIV prevention strategy. The past 2 years have seen significant new advances in knowledge regarding PrEP, including definitive demonstration that PrEP reduces the risk of HIV acquisition, regulatory approval of combination oral emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as the first PrEP agent with a label indication for sexual HIV prevention, and the development of normative guidance for clinical prescribing of PrEP. In PrEP clinical trials, HIV protection was strongly correlated with PrEP adherence; therefore, understanding and supporting adherence to PrEP are key to maximizing its public health impact. As would be expected for any new HIV prevention approach, questions remain, including how to motivate uptake of and sustain adherence to PrEP for HIV prevention in high-risk populations, how much use is sufficient to achieve HIV protection, and the potential of "next-generation" PrEP agents to improve this effective prevention strategy. At this important transition point-from demonstration of efficacy in clinical trials to thinking about implementation and effectiveness-this review addresses where we have been and where we are going with PrEP for HIV prevention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevention of HIV-1 infection with early antiretroviral therapy.
Cohen, M. S., Chen, Y. Q., McCauley, M., Gamble, T., Hosseinipour, M. C., Kumarasamy, N., Hakim, J. G., Kumwenda, J., Grinsztejn, B., Pilotto, J. H. S., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105243 · Cited by 6,873
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Grant, R. M., Lama, J. R., Anderson, P. L., McMahan, V., Liu, A. Y., Vargas, L., Goicochea, P., Casapía, M., Guanira-Carranza, J. V., Ramirez-Cardich, M. E., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1011205 · Cited by 5,096
Self-citationAntiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Baeten, J. M., Donnell, D., Ndase, P., Mugo, N. R., Campbell, J. D., Wangisi, J., Tappero, J. W., Bukusi, E. A., Cohen, C. R., Katabira, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1108524 · Cited by 3,256 · cited 5×
“Thus, just as consistent use of ART is needed to achieve HIV treatment benefits,21 adherence is critical to the efficacy of PrEP.”
BackgroundInfluentialSelf-citationAntiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
Thigpen, M. C., Kebaabetswe, P. M., Paxton, L. A., Smith, D. K., Rose, C. E., Segolodi, T. M., Henderson, F. L., Pathak, S. R., Soud, F. A., Chillag, K. L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110711 · Cited by 1,996
Cited by
Use of a vaginal ring containing dapivirine for HIV-1 prevention in women.
Baeten, J. M., Palanee-Phillips, T., Brown, E. R., Schwartz, K., Soto-Torres, L. E., Govender, V., Mgodi, N. M., Matovu Kiweewa, F., Nair, G., Mhlanga, F., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1506110 · Cited by 772
Self-citationDefining success with HIV pre-exposure prophylaxis: a prevention-effective adherence paradigm
Haberer, J. E., Bangsberg, D. R., Baeten, J. M., Curran, K., Koechlin, F., Amico, K. R., Anderson, P., Mugo, N., Venter, F., Goicochea, P., et al. (2015) · AIDS · doi:10.1097/qad.0000000000000647 · Cited by 319
Self-citationvan der Straten, A., Stadler, J., Montgomery, E., Hartmann, M., Magazi, B., Mathebula, F., Schwartz, K., Laborde, N., & Soto-Torres, L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089118 · Cited by 258
Kovarova, M., Council, O. D., Date, A. A., Long, J. M., Nochii, T., Belshan, M., Shibata, A., Vincent, H., Baker, C. E., Thayer, W. O., et al. (2015) · PLOS Pathogens · doi:10.1371/journal.ppat.1005075 · Cited by 77
Metadata
- Authors
- Baeten, J. M., Haberer, J. E., Liu, A. Y., & Sista, N.
- Venue
- JAIDS Journal of Acquired Immune Deficiency Syndromes
- Published
- 2013-07-01
- Volume
- 63
- Issue
- Supplement 2
- Pages
- S122-S129
- ISSN
- 1525-4135 (ISSN-L)
- OpenAlex
- W1999487971
- Cited by
- 158
- References
- 4
- FWCI
- 15.03
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Preexposure Prophylaxis for HIV Prevention: Where Have We Been and Where Are We Going? https://app.cochat.ai/papers/10.1097/qai.0b013e3182986f69
- The paper
- Baeten, J. M., Haberer, J. E., Liu, A. Y., & Sista, N. (2013). Preexposure Prophylaxis for HIV Prevention: Where Have We Been and Where Are We Going? JAIDS Journal of Acquired Immune Deficiency Syndromes. https://doi.org/10.1097/qai.0b013e3182986f69
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.